Company Expects FY 2026 Revenue of $80M to $85M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy LAB?
For fiscal year 2026, the Company expects revenue in the range of $80 million to $85 million, with seasonality similar to prior years.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LAB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LAB
Wall Street analysts forecast LAB stock price to rise
2 Analyst Rating
0 Buy
2 Hold
0 Sell
Hold
Current: 1.130
Low
1.35
Averages
1.35
High
1.35
Current: 1.130
Low
1.35
Averages
1.35
High
1.35
About LAB
Standard BioTools Inc. develops, manufactures and sells a diversified range of instrumentation, consumables, and services that help scientists and biomedical researchers. The Company's segments include Proteomics and Genomics. The Proteomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. The Company works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. It offers a diverse range of instrumentation, consumables, and services that generate data across early discovery, translational and clinical research.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Standard BioTools to Announce Q4 Earnings on February 24
- Earnings Announcement Date: Standard BioTools is set to release its Q4 earnings on February 24 after market close, with a consensus EPS estimate of -$0.03, reflecting a 66.7% year-over-year increase, while revenue is expected to decline by 60.4% to $18.5 million, indicating significant challenges ahead.
- Historical Performance Review: Over the past year, Standard BioTools has only beaten EPS estimates 25% of the time, while achieving a 100% success rate in beating revenue estimates, suggesting stability in revenue management but a need for improvement in profitability.
- 2025 Outlook: The company reported preliminary revenue of $85 million from continuing operations for 2025, exceeding estimates, although the overall outlook remains murky, which could impact investor confidence.
- Market Reaction Expectations: Given the significant revenue decline indicated in the upcoming earnings report, market reactions to Standard BioTools may lean negative, prompting investors to closely monitor how the company addresses its current financial challenges.
See More
Standard BioTools to Release Q4 and Full Year 2025 Financial Results
- Earnings Announcement: Standard BioTools Inc. will publish its fourth quarter and full year 2025 financial results on February 24, 2026, after U.S. market close, which is expected to provide investors with the latest insights into the company's operational performance.
- Technological Edge: As a leading solutions provider in biomedical research, Standard BioTools leverages its proprietary mass cytometry and microfluidics technologies to help researchers develop better medicines faster, thereby transforming scientific discoveries into improved patient outcomes.
- Market Focus: The company addresses pressing needs in translational and clinical research, particularly in oncology, immunology, and immunotherapy, highlighting its significant role in the biotechnology sector.
- Global Collaboration Network: Standard BioTools collaborates with leading academic, government, pharmaceutical, and biotechnology laboratories worldwide, aiming to provide reliable and repeatable insights into health and disease, further solidifying its market leadership.
See More
Standard BioTools Completes Sale of SomaLogic to Illumina
- Significant Transaction Value: Standard BioTools completed the sale of SomaLogic to Illumina for $350 million in cash, with an additional potential earnout of up to $75 million, bringing the total transaction value to $425 million, marking a major milestone in the company's strategic transformation.
- Strong Cash Reserves: Following the transaction, Standard BioTools estimates a cash and cash equivalents balance of approximately $550 million, providing robust financial resources for future M&A activities, thereby accelerating growth in a competitive industry landscape.
- Profitability Outlook: The company is on track to achieve positive adjusted EBITDA by 2026, reflecting improved operational efficiency and indicating a strong recovery capability in market competition, which enhances investor confidence.
- Long-Term Revenue Potential: Standard BioTools will receive a 2% royalty on net revenues from SOMAmer-based products for the next ten years, creating a stable revenue stream that supports ongoing innovation and market expansion strategies.
See More
STANDARD BIOTOOLS FINALIZES SALE OF SOMALOGIC TO ILLUMINA
- Sale Announcement: Standard Biotools has completed the sale of Somalogic to Illumina.
- Strategic Move: This acquisition is expected to enhance Illumina's capabilities in the field of genomics and proteomics.
See More
Neogen Corp (NEOG) Reports Q2 Earnings Beat, Shares Surge 28%
- Earnings Beat: Neogen Corp reported adjusted earnings of $0.10 per share for Q2, surpassing market expectations of $0.06, which significantly boosts investor confidence in the company's profitability.
- Sales Growth: The company achieved quarterly sales of $224.691 million, exceeding the forecast of $207.846 million, indicating strong market demand and promising future growth potential.
- Stock Surge: Following the earnings report, Neogen's stock price surged 28% to $9.44 on Thursday, reflecting a positive market sentiment and potentially attracting more investor interest.
- Guidance Upgrade: Neogen raised its FY26 sales guidance above market estimates, demonstrating confidence in future performance, which may further drive stock price appreciation and enhance competitive positioning in the market.
See More
Standard BioTools Projects $185 Million Revenue for 2025
- Quarterly Revenue Expectations: Standard BioTools anticipates approximately $56 million in combined revenue for Q4 2025, with about $24 million from continuing operations, indicating stable growth potential in the life sciences tools sector.
- Full-Year Performance Outlook: The company projects a total revenue of around $185 million for 2025, with approximately $85 million from continuing operations, reflecting ongoing development in its core business and strong market demand.
- Enhanced Strategic Flexibility: CEO Michael Egholm noted that the sale of SomaLogic to Illumina is on track to close in the first half of 2026, which is expected to provide the company with about $550 million in cash, significantly enhancing its capacity for future strategic investments.
- Stock Performance: Standard BioTools shares closed at $1.28 on Wednesday, up 0.78%, indicating market recognition of the company's growth potential moving forward.
See More
Standard BioTools to Announce Q4 Earnings on February 24
- Earnings Announcement Date: Standard BioTools is set to release its Q4 earnings on February 24 after market close, with a consensus EPS estimate of -$0.03, reflecting a 66.7% year-over-year increase, while revenue is expected to decline by 60.4% to $18.5 million, indicating significant challenges ahead.
- Historical Performance Review: Over the past year, Standard BioTools has only beaten EPS estimates 25% of the time, while achieving a 100% success rate in beating revenue estimates, suggesting stability in revenue management but a need for improvement in profitability.
- 2025 Outlook: The company reported preliminary revenue of $85 million from continuing operations for 2025, exceeding estimates, although the overall outlook remains murky, which could impact investor confidence.
- Market Reaction Expectations: Given the significant revenue decline indicated in the upcoming earnings report, market reactions to Standard BioTools may lean negative, prompting investors to closely monitor how the company addresses its current financial challenges.
See More
Standard BioTools to Release Q4 and Full Year 2025 Financial Results
- Earnings Announcement: Standard BioTools Inc. will publish its fourth quarter and full year 2025 financial results on February 24, 2026, after U.S. market close, which is expected to provide investors with the latest insights into the company's operational performance.
- Technological Edge: As a leading solutions provider in biomedical research, Standard BioTools leverages its proprietary mass cytometry and microfluidics technologies to help researchers develop better medicines faster, thereby transforming scientific discoveries into improved patient outcomes.
- Market Focus: The company addresses pressing needs in translational and clinical research, particularly in oncology, immunology, and immunotherapy, highlighting its significant role in the biotechnology sector.
- Global Collaboration Network: Standard BioTools collaborates with leading academic, government, pharmaceutical, and biotechnology laboratories worldwide, aiming to provide reliable and repeatable insights into health and disease, further solidifying its market leadership.
See More
Standard BioTools Completes Sale of SomaLogic to Illumina
- Significant Transaction Value: Standard BioTools completed the sale of SomaLogic to Illumina for $350 million in cash, with an additional potential earnout of up to $75 million, bringing the total transaction value to $425 million, marking a major milestone in the company's strategic transformation.
- Strong Cash Reserves: Following the transaction, Standard BioTools estimates a cash and cash equivalents balance of approximately $550 million, providing robust financial resources for future M&A activities, thereby accelerating growth in a competitive industry landscape.
- Profitability Outlook: The company is on track to achieve positive adjusted EBITDA by 2026, reflecting improved operational efficiency and indicating a strong recovery capability in market competition, which enhances investor confidence.
- Long-Term Revenue Potential: Standard BioTools will receive a 2% royalty on net revenues from SOMAmer-based products for the next ten years, creating a stable revenue stream that supports ongoing innovation and market expansion strategies.
See More
STANDARD BIOTOOLS FINALIZES SALE OF SOMALOGIC TO ILLUMINA
- Sale Announcement: Standard Biotools has completed the sale of Somalogic to Illumina.
- Strategic Move: This acquisition is expected to enhance Illumina's capabilities in the field of genomics and proteomics.
See More
Neogen Corp (NEOG) Reports Q2 Earnings Beat, Shares Surge 28%
- Earnings Beat: Neogen Corp reported adjusted earnings of $0.10 per share for Q2, surpassing market expectations of $0.06, which significantly boosts investor confidence in the company's profitability.
- Sales Growth: The company achieved quarterly sales of $224.691 million, exceeding the forecast of $207.846 million, indicating strong market demand and promising future growth potential.
- Stock Surge: Following the earnings report, Neogen's stock price surged 28% to $9.44 on Thursday, reflecting a positive market sentiment and potentially attracting more investor interest.
- Guidance Upgrade: Neogen raised its FY26 sales guidance above market estimates, demonstrating confidence in future performance, which may further drive stock price appreciation and enhance competitive positioning in the market.
See More
Standard BioTools Projects $185 Million Revenue for 2025
- Quarterly Revenue Expectations: Standard BioTools anticipates approximately $56 million in combined revenue for Q4 2025, with about $24 million from continuing operations, indicating stable growth potential in the life sciences tools sector.
- Full-Year Performance Outlook: The company projects a total revenue of around $185 million for 2025, with approximately $85 million from continuing operations, reflecting ongoing development in its core business and strong market demand.
- Enhanced Strategic Flexibility: CEO Michael Egholm noted that the sale of SomaLogic to Illumina is on track to close in the first half of 2026, which is expected to provide the company with about $550 million in cash, significantly enhancing its capacity for future strategic investments.
- Stock Performance: Standard BioTools shares closed at $1.28 on Wednesday, up 0.78%, indicating market recognition of the company's growth potential moving forward.
See More
